We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Safety Request Delays Novartis' Phase III Oral MS Therapy Trial
FDA Safety Request Delays Novartis' Phase III Oral MS Therapy Trial
June 22, 2005
The FDA has requested a safety analysis of a new Novartis multiple sclerosis (MS) treatment, prompting the drugmaker to delay the Phase III clinical trials of FTY720 by three or four months until the fourth quarter, Novartis announced June 21.